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Abstract
Capsaicin is the active compound responsible for the pungency of hot chilli. Research has discovered its ability to desensitize peripheral nociceptive fibers which is useful in treating chronic pain disorders, specifically neuropathic pain syndromes. Capsaicin treatment
comes in a variety of mediums including patches and creams and has been clinically proven to bring relief to patients with disorders
such as post herpetic neuralgia, chronic regional pain syndrome and HIV related neuralgia. Exciting new forms of treatment are also
in development and promise breakthroughs in the near future in this relatively young field of capsaicin-based analgesia.
Introduction
Chronic pain syndromes are debilitating, robbing many of their
quality of life and productivity while putting them at additional
risk of mental health disorders. Many do not find relief despite
extensive treatments. This has prompted research into finding
a compound that will present a viable alternative to traditional
analgesics, especially opiates which carry an additional risk of
addiction. Capsaicin, the compound responsible for the pungency of the capsicum family and an example of a vanilloid, has
been used as an analgesic agent for thousands of years. Recent
research has proven just how well suited it is as a treatment for
a subset of chronic pain disorders especially neuropathic pain.
This paper will look at the mechanisms of nociception that
are targeted by this treatment, the properties of capsaicin and
its receptor, TRPV1, that make it so effective. Its clinical applications and limitations will also be examined to give a glimpse of
what research has discovered and where it is taking us.

Mechanisms of Subcutaneous Primary Nociception
Nociception is the sensation of noxious stimuli perceived by nociceptive receptors which are usually found in the skin (Caterina
& Julius, 2001), although they can also be found viscerally. It is
the first step toward the sensation of pain which is the result
of a complicated multilayered process including central gating
controls and peripheral activity (Hunt, 2009). Nociception itself
is a complex process with aspects that take place in both the
central (CNS) and peripheral nervous systems (PNS).
There are two general categories of subcutaneous nociceptive
primary afferent neurons, myelinated A-fibers and unmyelinated
C-fibers. Not all A-fibers are sensitive to nociceptive stimuli, Aβ
fibers are large rapidly conducting fibers responsible for touch
and proprioception, and only Aδ fibers which are smaller and
slower conductors are involved in nociception (Khalid & Tubbs,
2017). Lightly-myelinated Aδ fibers are associated with acute
pain or first pain which is characterized by lancinating, stabbing,
or pricking pain that is felt immediately after exposure a noxious stimulus. Unmyelinated C-fibers are very slow conductors
and are responsible for second pain which is characterized by
the more global sensations of throbbing, burning or cramping
pain (Hunt, 2009; Dubin & Patapoutian, 2010).
Noxious stimuli are usually categorized as either heat (H), cold
(C), or mechanical (M). Primary nociceptive afferent fibers are further classified according to the type of stimuli that they respond to,
for example C-MH, A- MH. The most common C fibers are polymodal, meaning they respond to multiple types of stimulation such

as C-MC, C-MH and C-MHC.There is also a subgroup of C-fibers
known as silent C-MiHi that only become sensitive to noxious mechanical or thermal stimuli after he area has become sensitized by
inflammation. Most A-fibers are heat- or mechano- sensitive (A-H,
A-M, A-HM) (Dubin & Patapoutian, 2010).
Nociceptors have a variety of voltage gated channels that encode the intensity of the stimulus (Dubin & Patapoutian, 2010).
They also release neuropeptides that transmit input further up
the neural axis. For example, when C-fibers are triggered they
release glutamate and substance P (Hanpaa & Treede, 2012).
When the skin is injured it undergoes physiological changes
that protect it from further damage and promote healing, known
as inflammation. There are two subgroups of C-fibers. One of
them expresses the trkA receptor which binds to nerve growth
factor (NGF) and synthesizes neuropeptides such as CGRP
and substance P. When they are triggered they contribute to
inflammation and healing at the site of the injury (Hunt, 2009).
Symptoms of the inflammatory state include flare or reddening of
the immediate area and increased sensitivity to both innocuous
and noxious stimul,i both in the immediate and surrounding area.
The increased sensitivity is due to a reduced threshold of excitation in the C-fibers (Dubin & Patapoutian, 2010) and increased
receptor expression and excitation (Lebovitz, et al., 2012).
There is a second subgroup of C-fibers that do not have a role
in inflammation, instead they display the Ret receptor that binds
to GDNF and express PAP that breaks down ATP to produce
adenosine that, in turn, binds to the A1 receptor and reduces
nociception. In fact, intrathecal application of GDNF has been
shown to reduce neuropathic pain symptoms (Hunt, 2009).
C-fibers that are constantly in a state of excitation, such as
those in a chronic pain state, will release a constant flow of glutamate known as a glutamate barrage. This barrage may result
in physiological changes to the dorsal root ganglion and higher
pain areas of the brain that increases their sensitivity and excitability which is known as central sensitization. Descending controls may also have an impact on determining the sensitization
of dorsal root neurons (Hunt, 2009). Central sensitization may
also impact the sensitivity of A-fiber neurons, which don’t usually become sensitized, causing even innocuous stimuli to register
as painful (Baron, 2006). This may be a result of synapses that
they form with neurons that have been sensitized by C-fiber
barrage (Hunt, 2009).
Peripheral sensitization may also occur post-injury as a result of
physiological changes which may contribute to the development
of neuropathic pain syndromes (Gilron, Baron, & Jensen, 2015)
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The role that C-fibers and Aδ- fibers play in the process of
nociception is definitely an important one which makes them a
worthwhile target in the field of analgesia. These afferent neurons share a receptor TRPV1 which is expressed on all C-fibers
and a subset of Aδ fibers (Hunt, 2009; (Lebovitz, et al., 2012),
this means that if it can be shut off of blocked then peripheral
nociceptive input can be greatly minimized or even neutralized.
Targeting TRPV1 is especially prized because it allows a twopronged strategy against pain. Not only does targeting it , target
the beginning of the pain pathway (Trevisani & Szallasi, 2011;
Wagner, Roth-Daniek, Sell, England, & Kern, 2012), but it also
blocks the glutamate barrage which allows the body to break
the pain cycle common in chronic pain patients.

TRPV1
In 1990, the study of a more potent capsaicin analog, resiniferatoxin (RTX), led to the discovery of a new receptor known as
TRPV1. It’s name comes from the amino acid sequence that designates it’s membership in a family of receptors first identified in
fruit flies. In 1969 a mutation was identified on a visual receptor
of a fruit fly, instead of a sustained depolarizing after exposure
to light, these mutated receptors showed only transient depolarizing response to light, giving the family of receptors the name
transient receptor potential or TRP. The second part of its name,
V1, comes from the amino acid sequence that was identified that
marked it as a vanilloid receptor (Caterina & Julius, 2001). The
amino acid strain was first designated VR1 but when it was joined
to the receptor family it was abbreviated to TRPV1.
The discovery of TRPV1 led to the discovery of a subset
of thermal-sensitive TRP-type receptors which are also called
thermoTRPs (Trevisani & Szallasi, 2011). Other members of
this family include TRPV2, TRPV3 and TRPV4. TRPV1 is highly
expressed on normal nociceptive C-fibers and Aδ-fibers and
after inflammation show increased upregulation and sensitivity
(Lebovitz, et al., 2012). It is part of the nociceptive pathway and
is activated by a variety of stimuli including protons, noxious
heat, phorbol esters, fatty acids as well as vanilloids like capsaicin and RTX. The receptor only experiences maximum activation when activated by multiple types of stimuli (Vyklicky, et
al., 2008), which is consistent with the polymodal nature of the
C-fibers that are involved in nociception.
TRPV1 has been proved to be involved in many forms of
pathophysiology including inflammatory bowel syndrome (IBS),
osteoarthritis, rheumatoid arthritis, post herpetic neuralgia
(PHN) and cystitis amongst others (Andreev, et al., 2013). This
makes understanding this receptor necessary for the treatment
of many different disorders.
There are two ways that TRPV1 can be targeted pharmacologically, either it can be desensitized by vanilloids or blocked
by antagonists.There are two types of desensitization, acute desensitization and tachyphylaxis, which is a reduction in response
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to noxious stimuli as a result of repeated application (Vyklicky,
et al., 2008). There is also a difference between high dosage and
low dosage desensitization such as between the short-term
refractory period that takes place after any application of a
vanilloid and longer lasting defunctionalization that takes place
after the administration of a high dosage application (Finch &
Drummond, 2015) (Trevisani & Szallasi, 2011).
Multiple biomechanisms have been discovered by researchers
to have a role in the process of sensitization and desensitization of the TRPV1 receptor including the phosphorylation and
dephosphorylation of the receptor (Trevisani & Szallasi, 2011),
although the process isn’t fully understood. The dramatic influx
of Ca2+ ions in the primary afferent neurons that takes place
during vanilloid applications have also proved to be a part of
the long-term desensitization mechanism (Vyklicky, et al., 2008).
Vanilloid induced messenger plasticity, which refers to changes
in the expression of neuropeptides on the receptor such as
a decrease of the proinflammatory neuropeptide SP and the
increase of analgesic peptide galanin, and is also part of the longterm desensitization or ‘defunctionalization’ associated with the
application of high dosage capsaicin.
Antagonists that block the TRPV1 receptor are a popular avenue of research, but many promising leads often lead to disaster.
These compounds often induce spontaneous hypothermia in
humans making them impractical for use. However, there have
been promising breakthroughs by a group in Russia with a compound that only partially blocked the receptor which shows
that partial blockage of the receptor may be a better outcome
than a full blockage (Andreev, et al., 2013). This is backed up
by research that has shown that partial binding is enough to
activate the TRPV1 receptor and that there are multiple levels
of activation based on the state of binding of the receptor (Hui,
Liu, & Qin, 2003).
There used to be a theory that the main function of TRPV1
is thermoregulation. This was based on its role in thermal sensitivity and the hypothermic effect of capsaicin and TRPV1 antagonists, but this was later mostly debunked (Trevisani & Szallasi,
2011). Other studies have also shown that the gene deletion
of TRPV1 in mice still allowed for a level of noxious thermal
sensitization (Dubin & Patapoutian, 2010).
TRPV1 is the therapeutic focus of a common analgesic and
other drugs on the market. Paracetamol or acetaminophen is
thought to interact with TRPV1 as part of its analgesic mechanism. Also drugs such as Taramidol which is used to treat fibromyalgia and nefopam, a benzoxazocine analgesic, also interact
with TRPV1.There are also compounds in Eastern medicine that
may target TRPV1 (Trevisani & Szallasi, 2011).

Capsaicin
Capsaicin, or 8-methyl-N-vanillyl-noneamid, is the compound
responsible for the pungency of hot chili peppers (Factor, et al.,
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2011) which are of the genus capsicum (Finch & Drummond,
2015). Any ingestion of hot chili will cause a painful burning sensation. However, perhaps ironically, capsaicin has been proved
to have extensive analgesic qualities. It is also a potential neurotoxin and large doses can cause permanent nerve damage
(Trevisani & Szallasi, 2011).
For thousands of years capsaicin extracts were used as part
of native medicine as a primitive analgesic. Aztec physicians may
have used it to treat tooth ache and sources show that RTX,
which is derived from the latex of the palm Euphoria Resinifera,
may have been used in Ancient Rome to treat the arthritis of
the Emperor Augustus. In Northern India a native plant containing capsaicin called bhut jolokial has been used by the people
who live there to treat arthritis (Finch & Drummond, 2015).
Modern pharmacy, however, was late to discover its qualities
and did not recognize it’s potential until the year1878 (Trevisani
& Szallasi, 2011).
The Hungarian chemist Endre Hӧgyes is credited with the
discovery of the effect of capsaicin on sensory fibers but his
find remained lost until the turbulent years and scientific innovation of World War Two. Another Hungarian chemist, Nicholas
(Miklόs) Jancsό further developed the use of capsaicin by developing its potential as a promising analgesic. In the 1970’s capsaicin research exploded, with the number of papers on record
jumping exponentially. Capsaicin continues to be of a topic of
interest for the general scientific community and continues to
be extensively researched until today (Trevisani & Szallasi, 2011).
Originally the analgesic properties of capsaicin were though
to come from its counterirritant and warming properties
(Hanpaa & Treede, 2012) but now we know that there are many
mechanisms involved (Vyklicky, et al., 2008). It is a TRPV1 agonist
(Factor, et al., 2011) and it is the complex interaction between
TRPV1 and capsaicin that is the crux of its analgesic abilities.
Initial exposure to capsaicin activates the TRPV1 ligand gated
channels on the primary afferent nociceptive neurons which
cause depolarization, the initiation of an action potential and
transmission of a pain signal to the spinal cord (Backonja, et
al., 2008). This is followed by a lasting refractory period know
as desensitization (Factor, et al., 2011) and if the dose is high
enough it generates a longer lasting local desensitization which
is also known as defunctionalization (Finch & Drummond, 2015).
In high dose applications when TRPV1 is activated, high levels of calcium enter the cell overwhelming the mitochondria
and causing apoptosis. The nociceptive nerve fibers in the area
where the capsaicin is administered begin to die which prevents
the initiation of new nociceptive input, causing a defunctionalization of the nociceptive ability in that area.) After the application of a high dose capsaicin patch for one week there was an
80% decrease in the density of epidermal nerve fibers (ENFs).
However, if the dosage is not too high the damage is reversible,
which was corroborated by the study. Partial regeneration was

present twelve weeks after the treatment and complete regeneration at twenty-four weeks (Wallace & Pappagallo, 2011).
This is consistent with the pain relief that patients who use high
dosage capsaicin treatment experience, often pain relief lasts for
up to three months per application (Finch & Drummond, 2015).
This is one of the reasons that capsaicin is so well suited to
treating chronic pain, especially neuropathic pain. Long lasting,
comprehensive relief without daily drug use is very attractive
for chronic pain sufferers. Also, the ability of capsaicin to temporarily destroy nociceptive nerve endings provides a way to cut
off nociceptive input, the glutamate barrage to the spinal cord.
This allows the spinal cord and higher pain areas to minimize or
perhaps extinguish the effects of central sensitization or ‘windup,’ which is the hyperactivity of neurons in the spinal cord and
brain, due to neuroplasticity that makes them extra sensitive to
pain input. Central sensitization is characteristic of neuropathic
pain and extremely hard to treat. Doctors who have been using
the high dose capsaicin patch have reported anecdotally a reduction in the symptoms of windup in their patients (Wagner,
Roth-Daniek, Sell, England, & Kern, 2012).

Medications
There are many forms of capsaicin based pharmacological treatments. Initially, low dose, topical creams were the form of choice,
but studies found them to have a disappointing effect. In a comprehensive study they were found, at best, to have a moderate effect
and many subjects reported poor or no effect (Trevisani & Szallasi,
2011). The creams come in two different strengths 0.075% under
the name Zostrix® (Finch & Drummond, 2015) and 0.025% with
lidocaine under the name Axain® (Trevisani & Szallasi, 2011).
The most popular form of capsaicin-based treatment is the
Quetenza® 8% patch. The dosage of the patch is significantly
higher than the creams which allows the treatment to enable
long-term desensitization within the treatment area. The patch
promises relief for up to three months (Wallace & Pappagallo,
2011) which is consistent with capsaicin mediated nerve fiber
death.. This means that the patch only needs to be reapplied
every three months, which greatly increases patient compliance.
The potential for capsaicin to cause irreversible nerve damage may make physicians wary of using the high potency patch.
However, a study shows that the recommended dosage of up
to four patches per application (Wallace & Pappagallo, 2011)
is within estimated dietary consumption of cultures that consume a diet heavy in capsaicin such as Mexico,Thailand and India
(Hanpaa & Treede, 2012).
The patch has shown to be effective for a variety of syndromes and can be cut to size so that it can be applied almost
anywhere on the body. Capsaicin’s unique mechanism of analgesia means that it has no known drug interactions which allows
it to be incorporated into a treatment plan that includes other
analgesics too (Wallace & Pappagallo, 2011).

21

Mimi Kornwasser

Other forms of capsaicin include an injectable form that can
be used to treat osteoarthritis, tendonitis and some forms of
neuropathic pain. There is also an intranasal form that has been
clinically proven to be effective in the treatment of migraines
(Trevisani & Szallasi, 2011).

Clinical Applications
Capsaicin treatment has been adapted for the treatment of many
disorders. The most obvious of these are pain related including
PHN, stump pain, headaches, trigeminal neuralgia and osteoarthritis amongst others (Wagner, Roth-Daniek, Sell, England, & Kern,
2012). Interestingly, capsaicin has also been used for the treatment of urinary incontinence as well (Trevisani & Szallasi, 2011).
The treatment of PHN by capsaicin has been the focus of many
studies into the efficacy of capsaicin- based analgesia. PHN is one
of the most common forms of neuropathic pain after chronic
back pain and painful diabetic neuropathy (Wallace & Pappagallo,
2011). PHN is a chronic pain disorder that develops the varicella
zoster (shingles) virus comes out of dormancy.The treatment options of PHN are limited and often poorly tolerated which makes
the disorder very hard to treat (Backonja, et al., 2008). However,
multiple studies that have investigated the outcome of using a
capsaicin patch have seen favorable results with minimal side effects and marked relief experienced by the patient (Backonja, et
al., 2008; Wallace & Pappagallo, 2011). Some patients with HIV
associated neuropathy have also reported relief from capsaicin
patch treatments (Capsaicin dermal patch: a guide to its use in
non-diabetic peripheral neuropathic pain, 2011).
A tertiary hospital studied the results of their hospital-wide
adoption of capsaicin patches to treat non-diabetic patients
with a variety of neuropathic pains.These included PHN, CRPS-I,
knee arthroplasty related pain, painful scaring, femoral cutaneous neuropathy, HIV related neuropathy and neuroma. They
found a 23% reduction of pain in a population of twenty patients
that had been treated with the patches.They also noted that six
of the patients had not found relief with any other treatment
that they had tried so far. They also found that patients that had
a higher basal quality of life experienced a better response to
the drug (Gimenez-Mila, et al., 2014).
A novel way that capsaicin is being used is to facilitate rehabilitation for knee arthroplasty patients. Often pain following knee
arthroplasty surgery can impede recovery and rehabilitation,
leading to prolonged hospital stays and a more painful, prolonged
recovery. Capsaicin has been introduced as a novel way to dull
the pain through temporary desensitization of the local area for
the duration of the initial recovery.This allows the patient to proceed with exercises and activities that will improve their function
and help them get back on their feet quicker. It was expected that
patients may report increased post-operative pain because the
capsaicin had been applied, but pain scores were found to be well
within range (Hartrick, Pestan, Carlson, & Hartrick, 2011).
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Trials of capsaicin being used as ‘molecular scalpels’ for the
treatment of cancer-related neuropathic pain are showing
promising signs (Trevisani & Szallasi, 2011). The principle behind this method of treatment is that physicians can use the
neurotoxic ability of capsaicin to target very specific cells to
treat chronic, intractable pain that cancer patients experience.
The treatment carries obvious risks which is probably why the
clinical applications that are being pursued right now are very
limited, but the potential of this technique is very exciting.

Drawbacks
Although capsaicin is an exciting new frontier in analgesia it has
some risks and limitations that must be addressed. Exposure of
the mucosa of the throat to capsaicin can cause coughing and
bronchoconstriction. However, bronchoconstriction from such
a scenario is very rare and even coughing had a very low incidence rate during the clinical trials (Wallace & Pappagallo, 2011).
Capsaicin can only be applied to a local area. In high doses
that would be needed to give systemic relief it can cause a drop
in body temperature and may be cardiotoxic (Lebovitz, et al.,
2012). The hypothermic effect of capsaicin is posited to be a
result of the defunctionalization of the TRPV1 receptor. This
warps the thermosensitivity of the preoptic heat sensors and
fools the animal into thinking that they are warm. This is reflected in the animal’s loss of ability to regulate their own body
temperature (Trevisani & Szallasi, 2011).
Researchers have also found a correlation between a diet high
in spicy food and an elevated risk of cancer. However, further
research needs to be done to see if this is applicable to all forms
of capsaicin exposure or just ingestion of capsaicin. Capsaicin
is poorly metabolized by the skin (Wallace & Pappagallo, 2011)
so topical application may not carry the same risk of ingestion.
The patch system, despite having many advantages, has the
drawback of needing a minimal infrastructure and attending
medical personnel to a be able to incorporate them into a treatment plan (Gimenez-Mila, et al., 2014). Also, they often require
the administration of a local topical anesthetic such as Lidocaine
before application due to the sensation of painful burning that
is experienced during the hour long application time (Wagner,
Roth-Daniek, Sell, England, & Kern, 2012).
The disadvantage of the creams is that they require multiple,
daily applications which greatly decreases patient compliance. It
may also induce a painful burning sensation that will discourage
its application and hasn’t even been proven to be an effective
analgesic because of its low dosage (Backonja, et al., 2008).

Conclusions
The ingenuity that is being employed to find pathology and techniques suited to capsaicin treatment is astounding and there is
no doubt that the scientific community will continue to come
up with new ways to use the unique capabilities of capsaicin
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to treat other pathologies. However, there is a need for the
development of a standardized schedule of treatment for using
capsaicin in a clinical setting (Factor, et al., 2011).
A better understanding of the biology of neuropathic pain
would also be an advantage for the development of capsaicin-based pharmacology. If the mechanisms of pain disorders
were better understood, treatments could be targeted to directly counteract them in a technique similar to the molecular
scalpel being used for cancer-related neuropathic pain.
Perhaps capsaicin could also be adapted for the treatment of
phantom limb pain (PLP). The source of PLP is a combination of
sensitization and inflammation that takes place in both the central and peripheral nervous systems. Perhaps the desensitizing
ability of capsaicin could be effective in this scenario by reducing
peripheral sensitization and central nervous system input.
Capsaicin is a novel pharmacological agent that promises an
alternative to traditional analgesics and opioids in the treatment
of neuropathic pain and other pain syndromes. Research into
capsaicin is fairly recent but clinical data has yielded favorable
results and new research seems hopeful of making new breakthroughs in techniques and applications of capsaicin in medicine.
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